Biogen’s Aduhelm Sales Total $2 Million in the Second Quarter

Pharmaceutical manufacturer Biogen reported its on thursday Controversial Alzheimer’s drug aduhelm It brought in $2 million in its first few weeks, which is the first revenue for a treatment that is expected to generate billions of dollars in a few years and strain Medicare’s budget. The company did not disclose the number of patients who …

Cleveland Clinic Says It Won’t Give Patients Aduhelm

In a striking reflection of the concern over approval of the controversial new Alzheimer’s drug Aduhelm, the Cleveland Clinic said Wednesday evening that it will not be administering it to patients. The clinic, one of the nation’s largest and most respected medical centers, said in a statement that a panel of experts “reviewed all available …